What is the recommended dosage of the Lao version of Ixazomib?

Ixazomib is a medication indicated for the treatment of multiple myeloma, exerting its therapeutic effect by inhibiting the growth of cancer cells. This malignancy may affect the bones and kidneys, and impair the body's ability to produce healthy red blood cells, white blood cells, and platelets.

What is the recommended dosage of the Lao version of Ixazomib?

The dosage of this medication varies from patient to patient; please follow the instructions of your physician or the information provided in the package insert. The following content only includes the general average dosage. Do not adjust your dosage on your own if it differs from the stated amount, unless specifically directed by a doctor.

The dosage administered depends on the drug concentration. Additionally, the daily frequency of administration, dosing intervals, and duration of treatment must be determined based on the specific condition of the patient.

Oral Capsule Formulation

For multiple myeloma (in combination with lenalidomide and dexamethasone):

Adults: The initial dosage is 4 mg per administration, once weekly, taken on Days 1, 8, and 15 of a 28-day treatment cycle. The doctor may adjust the dosage as needed.

Pediatric patients: The dosage and administration method must be determined by a physician.

Management of Missed Doses

If vomiting occurs after taking the medication, contact your doctor or pharmacist immediately.

If a dose is missed and more than 72 hours remain before the next scheduled dose, take the missed dose at once. If fewer than 72 hours remain, skip the missed dose and resume the regular dosing schedule. Do not take an extra dose if vomiting occurs after administration; continue with subsequent doses at the originally scheduled times.

Use of Ixazomib in Special Populations

Patients with hepatic impairment

Dose adjustment is required for patients with renal impairment. For patients with total bilirubin levels greater than 1.5 times the upper limit of normal (ULN), it is recommended to initiate treatment at a dosage of 3 mg per administration on Days 1, 8, and 15 of a 28-day cycle.

Patients with renal impairment

For patients with a creatinine clearance rate below 30 mL/min, it is recommended to initiate treatment at a dosage of 3 mg per administration on Days 1, 8, and 15 of a 28-day cycle.

Precautions during pregnancy

No human data are available. Animal studies suggest potential risks of skeletal abnormalities, embryotoxicity, and reduced fetal body weight. Physicians must weigh the benefits of treatment against the potential risks. Pregnancy testing should be performed before the initiation of treatment. Patients must use non-hormonal contraceptive methods to avoid pregnancy during treatment and for 90 days after discontinuation of the drug.

Precautions during lactation

Breastfeeding should be avoided during treatment and for 90 days after discontinuation of the drug.

Pediatric patients

Ixazomib is not approved for use in pediatric patients.

Geriatric patients

Clinical studies have demonstrated that the addition of ixazomib to the standard regimen of lenalidomide plus low-dose dexamethasone confers a clinically meaningful progression-free survival benefit. However, these studies did not include patients aged 75 years or older.

Adverse Reactions of Ixazomib

The most common adverse reactions of ixazomib include thrombocytopenia, neutropenia, nausea, vomiting, diarrhea, constipation, rash, peripheral neuropathy, peripheral edema, and back pain. In the TOURMALINE MM1 study, the incidence of these reactions exceeded 20%. Among them, the most severe common adverse reactions are thrombocytopenia and diarrhea. Some adverse events may worsen, particularly hepatotoxicity, neuropathy, neutropenia, and thrombocytopenia. Other potential adverse reactions include thrombotic microangiopathy, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, and Stevens-Johnson syndrome.

A small number of patients taking ixazomib may experience ocular abnormalities such as blurred vision, dry eye syndrome, and conjunctivitis. It is important to note that proteasome inhibitors are known to cause peripheral neuropathy, and ixazomib carries this risk as well, although its incidence is lower than that of bortezomib, a drug in the same class.